B of A Securities Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $388
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $266 to $388.
B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $266 to $388.